Dr. Thomas Colletti
Purpose: The purpose of this article is to review and discuss the treatment of metastatic and high-risk melanoma over the last 10 years. This includes discussing new immunotherapy options, as well as new targeted therapy.
Method: A PubMed and Google Scholar search was conducted using the terms melanoma, metastatic melanoma, immunotherapy, ipilimumab, nivolumab, pembrolizumab, and targeted therapies.
Results: Significant evidence- based studies demonstrating the efficacy of immunotherapy, such as: ipilimumab, nivolumab, and pembrolizumab in the treatment of metastatic melanoma. In addition, evidence- based studies demonstrating the efficacy of targeted therapies for BRAF mutated melanoma.
Conclusion: The introduction of immunotherapy and targeted therapies in the last 10 years has dramatically changed the prognosis for high risk and metastatic melanoma. Over 50% of patients will respond to these treatments; however, there is still a need for additional therapies for those who are unresponsive to current treatments.
Keywords: ipilimumab, pembrolizumab, nivolumab, melanoma, BRAF
Byrne, Joy Mullins
"The Evolution of Melanoma Management Over the Last 10 Years,"
Lynchburg Journal of Medical Science: Vol. 3
, Article 18.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol3/iss3/18
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.